
President Trump's "big, beautiful bill" threatens Medicaid access for millions in Florida, advocates warn
The Florida Health Justice Project estimates the legislation will cut about $4 billion annually in federal Medicaid support to the state, impacting at least one million current recipients. While it's unclear exactly who will lose coverage, advocates say the most vulnerable populations — including elderly residents who rely on Medicaid to help pay for Medicare premiums and legal immigrants with temporary status — will be among the first affected.
"There's really just one step away from sheer panic," said Lynn Hearn of the Florida Health Justice Project. "If you have a person with a severe disability, they are relying upon the services of Medicaid literally to stay alive."
In Florida, roughly four million low-income individuals or people with disabilities depend on Medicaid, the government-funded health insurance program.
Florida residents with disabilities fear tighter Medicaid restrictions
Paolo Linares, a Liberty City resident, is among them. Diagnosed with autism and ADHD, she lives at home but was hoping to gain independence by moving out.
She said the new restrictions could make Medicaid inaccessible when she needs it most.
"This type of paperwork may make it harder in the case that I may need it," Linares said. "If you're going to put more stricter things on this, what are you going to do to help these people?"
Clinics may close as Medicaid cuts ripple through Florida's health system
The ripple effects could reach beyond Medicaid recipients. Hearn said as fewer people are able to seek care, medical providers may not be able to stay in business — affecting access for even those who remain insured.
"When there aren't as many people who are insured and able to go to the doctor and get services, then those service providers aren't able to maintain their business," she said. "And then they shut down."
Among those expected to lose coverage are refugees, asylum seekers, parolees, and others from countries like Afghanistan and Syria who are in the U.S. legally but lack permanent resident status.
"These are people who have been able to get coverage for their families, but that will end," Hearn said.
She added that the next state budget cycle will likely force Florida to make tough choices about what Medicaid benefits to continue funding.
For now, the Florida Health Justice Project said it will focus efforts on lobbying state lawmakers to secure alternative funding for the program.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles

33 minutes ago
Planned Parenthood sues Trump admin, saying it is targeted by provision in megabill
A federal judge in Massachusetts granted a temporary restraining order against a provision in President Donald Trump's recently passed tax and policy megabill that would deny Planned Parenthood and its member organizations Medicaid funding for one year for non-abortion health services. Planned Parenthood, the largest reproductive health provider in the United States, and two of its member organizations had filed a lawsuit against the Trump administration earlier Monday over the provision, which the groups said was meant to target Planned Parenthood and its member organizations over abortion access. While the Hyde Amendment already prohibits the use of federal funding for abortions, the provision would prevent providers that offer abortion services and that received over $800,000 or more in federal Medicaid funding in 2023 from receiving Medicaid funding for other kinds of care for one year. Judge Indira Talwani, who was nominated by former President Barack Obama, wrote in the temporary restraining order that "Defendants, their agents, employees, appointees, successors, and anyone acting in concert or participation with Defendants shall take all steps necessary to ensure that Medicaid funding continues to be disbursed in the customary manner and timeframes to Planned Parenthood Federation of America and its members; Planned Parenthood League of Massachusetts; and Planned Parenthood Association of Utah." The order is set to remain in effect for 14 days, and a hearing has been set for July 21. Planned Parenthood, in a statement on social media on Monday night, wrote, "We're grateful that the court acted swiftly to block this unconstitutional law attacking Planned Parenthood providers and patients... The fight is just beginning, and we look forward to our day in court!" In its lawsuit, Planned Parenthood wrote that the bill's provision was meant "to categorically prohibit health centers associated with Planned Parenthood from receiving Medicaid reimbursements… in order to punish them for lawful activity, namely advocating for and providing legal abortion access wholly outside the Medicaid program and without using any federal funds." Mentioning that Planned Parenthood branches serve over a million patients using Medicaid each year, the group wrote, "losing the ability to choose a Planned Parenthood Member health center as their Medicaid provider will be devastating for Medicaid patients across the country." The group also said that Planned Parenthood clinics, services, and staff would likely be eliminated if the clinics can no longer get Medicaid reimbursement. The lawsuit names Secretary of Health and Human Services (HHS) Robert F. Kennedy, Jr. and Centers for Medicare & Medicaid Services (CMS) administrator Mehmet Oz, along with their respective agencies, as plaintiffs. ABC News has reached out to HHS and CMS for comment. Multiple groups that oppose abortion access condemned the lawsuit, calling the bill a win for their cause and framing Planned Parenthood as desperate. "Planned Parenthood's desperation is showing as they run to the courts again to fix a crisis of their own making. Time after time they rely on unelected judges to bail them out of trouble, rather than fix deep systemic problems internally... As Planned Parenthood doubles down on lawfare and abortion politics, they prove exactly why the One Big Beautiful Bill is a historic victory for the people, stopping half a billion dollars in forced taxpayer funding of the corrupt abortion industry for the first time," Susan B. Anthony Pro-Life America director of legal affairs Katie Daniel said in a statement.
Yahoo
34 minutes ago
- Yahoo
Celltrion USA announces U.S. launch of denosumab biosimilars, STOBOCLO® and OSENVELT® (denosumab-bmwo)
STOBOCLO® (denosumab-bmwo) and OSENVELT® (denosumab-bmwo) are approved by FDA for all indications of PROLIA® (denosumab) and XGEVA® (denosumab) respectively[1],[2] STOBOCLO and OSENVELT, among the first wave of biosimilars referencing PROLIA and XGEVA respectively, are commercially available in the U.S. Celltrion further expands its portfolio, delivering cost-effective and high-quality biologic medicines to wider range of patients in the U.S. JERSEY CITY, N.J., July 7, 2025 /PRNewswire/ -- Celltrion USA today announced that STOBOCLO® (denosumab-bmwo) and OSENVELT® (denosumab-bmwo), biosimilars referencing PROLIA® (denosumab) and XGEVA® (denosumab) respectively, are commercially available in the United States. STOBOCLO is available in 60 mg/mL injection and is approved to treat postmenopausal women with osteoporosis at high risk for fracture, to increase bone mass in men with osteoporosis at high risk for fracture, to treat glucocorticoid-induced osteoporosis in men and women at high risk for fracture, to increase bone mass in men at high risk for fracture receiving androgen deprivation therapy for nonmetastatic prostate cancer, and to increase bone mass in women at high risk for fracture receiving adjuvant aromatase inhibitor therapy for breast cancer.[1] OSENVELT is available in 120 mg/1.7 mL (70 mg/mL) injection and is indicated to prevent skeletal-related events in patients with multiple myeloma and in patients with bone metastases from solid tumors, to treat adults and skeletally mature adolescents with giant cell tumor of bone that is unresectable or where surgical resection is likely to result in severe morbidity, and to treat hypercalcemia of malignancy refractory to bisphosphonate therapy.[2] "We are pleased to have achieved a global settlement with Amgen regarding our denosumab biosimilars," said Thomas Nusbickel, Chief Commercial Officer at Celltrion USA. "We are proud to introduce our denosumab biosimilars to the U.S. market, offering patients and healthcare professionals a valuable alternative treatment option. Building on our strong heritage in biosimilars, Celltrion remains committed to being a trusted partner for both patients and physicians, while contributing to the overall sustainability of healthcare systems." STOBOCLO and OSENVELT are supported by Celltrion's comprehensive patient support programs designed to help empower patients to navigate their treatment journeys. Celltrion offers a suite of resources, including the Celltrion CONNECT® Patient Support Program and the Celltrion CARES™ Co-pay Assistance Program. Patients who are uninsured may be able to receive STOBOCLO and OSENVELT at no cost. Visit and to learn more. Celltrion's biosimilars portfolio covers the areas of immunology, oncology, gastroenterology, allergy, and endocrinology. About STOBOCLO® (denosumab-bmwo) STOBOCLO® (denosumab-bmwo) is a receptor activator of NF-κb ligand (RANKL) inhibitor referencing PROLIA® (denosumab). STOBOCLO 60 mg/mL injection is approved by the FDA based on comprehensive data and clinical evidence confirming the therapeutic equivalence to PROLIA. In the U.S., STOBOCLO is approved to treat postmenopausal women with osteoporosis at high risk for fracture, to increase bone mass in men with osteoporosis at high risk for fracture, to treat glucocorticoid-induced osteoporosis in men and women at high risk for fracture, to increase bone mass in men at high risk for fracture receiving androgen deprivation therapy for nonmetastatic prostate cancer, and to increase bone mass in women at high risk for fracture receiving adjuvant aromatase inhibitor therapy for breast cancer. INDICATIONS STOBOCLO® (denosumab-bmwo) is a RANK ligand (RANKL) inhibitor indicated for treatment: of postmenopausal women with osteoporosis at high risk for fracture to increase bone mass in men with osteoporosis at high risk for fracture or in men at high risk for fracture receiving androgen deprivation therapy for nonmetastatic prostate cancer of glucocorticoid-induced osteoporosis in men and women at high risk for fracture to increase bone mass in women at high risk for fracture receiving an adjuvant aromatase inhibitor therapy for breast cancer IMPORTANT SAFETY INFORMATION WARNING: SEVERE HYPOCALCEMIA IN PATIENTS WITH ADVANCED KIDNEY DISEASE Patients with advanced chronic kidney disease, including those on dialysis, face a higher risk of severe hypocalcemia after denosumab administration, with reported cases leading to hospitalization, life-threatening events, and fatalities. The presence of chronic kidney disease-mineral bone disorder (CKD-MBD) markedly increases the risk of hypocalcemia in these patients Before starting STOBOCLO® (denosumab-bmwo) in advanced chronic kidney disease patients, assess for CKD-MBD. Treatment should be supervised by a healthcare provider experienced in diagnosing and managing CKD-MBD. STOBOCLO is contraindicated in hypocalcemia, pregnant women, and in patients with known hypersensitivity to denosumab. Severe Hypocalcemia: Ensure adequate calcium and vitamin D; monitor for severe hypocalcemia. Drug Products with Same Active Ingredient: Do not use with other denosumab products. Hypersensitivity: If an anaphylactic or other clinically significant allergic reaction occurs, initiate appropriate therapy and discontinue further use of STOBOCLO. Osteonecrosis of the Jaw (ONJ): ONJ can occur in patients on STOBOCLO. Conduct oral exams before treatment; maintain oral hygiene; consider discontinuation of STOBOCLO if ONJ develops. Atypical Subtrochanteric and Diaphyseal Femoral Fractures: Monitor for thigh, hip, or groin pain; evaluate for fractures. Interruption of STOBOCLO therapy should be considered, pending a benefit-risk assessment, on an individual basis. Multiple Vertebral Fractures (MVF) Following Discontinuation of Treatment: Increased risk post-discontinuation of denosumab; transition to alternative therapy if discontinuing STOBOCLO. Serious Infections: Higher risk in denosumab users; assess benefit-risk profile, especially in immunocompromised patients. Assess the benefit-risk profile before starting STOBOCLO and reconsider its use if serious infections develop. Dermatologic Adverse Reactions: Consider discontinuing STOBOCLO if severe dermatitis, eczema, or rashes occur. Musculoskeletal Pain: Consider discontinuation of STOBOCLO if severe pain develops. Bone Turnover Suppression: In clinical trials in women with postmenopausal osteoporosis, denosumab significantly suppressed bone remodelling; patients should be monitored for these outcomes. Hypercalcemia in Pediatrics Patients with Osteogenesis Imperfecta: Not for pediatric use; hypercalcemia reported in patients osteogenesis imperfecta treated with denosumab products. Most common Adverse Reactions: In (>5%) of patients with: Postmenopausal osteoporosis were back pain, pain in extremity, hypercholesterolemia, musculoskeletal pain, and cystitis. Pancreatitis has been reported in clinical trials. Male osteoporosis were back pain, arthralgia, and nasopharyngitis. Glucocorticoid-induced osteoporosis (> 3%) were back pain, hypertension, bronchitis, and headache. Bone loss due to hormone ablation for cancer (≥ 10%) were arthralgia and back pain. Pain in extremity and musculoskeletal pain have also been reported in clinical trials. For more information, see Full Prescribing Information. About OSENVELT® (denosumab-bmwo) OSENVELT® (denosumab-bmwo) is a receptor activator of NF-κb ligand (RANKL) inhibitor referencing XGEVA® (denosumab). OSENVELT 120 mg/1.7 mL (70 mg/mL) injection is approved by the FDA based on a robust clinical trial and comprehensive data confirming the therapeutic equivalence to XGEVA. In the U.S., OSENVELT is indicated to prevent skeletal-related events in patients with multiple myeloma and in patients with bone metastases from solid tumors, to treat adults and skeletally mature adolescents with giant cell tumor of bone that is unresectable or where surgical resection is likely to result in severe morbidity, and to treat hypercalcemia of malignancy refractory to bisphosphonate therapy. INDICATION OSENVELT® (denosumab-bmwo) is indicated for: Prevention of skeletal-related events in patients with multiple myeloma and in patients with bone metastases from solid tumors. Treatment of adults and skeletally mature adolescents with giant cell tumor of bone that is unresectable or where surgical resection is likely to result in severe morbidity. Treatment of hypercalcemia of malignancy refractory to bisphosphonate therapy. IMPORTANT SAFETY INFORMATION Contraindications: Patients with hypocalcemia or with known clinically significant hypersensitivity to denosumab products. Drug Products with Same Active Ingredient. Patients receiving OSENVELT should not receive other denosumab products concomitantly. Hypersensitivity. If an anaphylactic or other clinically significant allergic reaction occurs, initiate appropriate therapy and discontinue further use of OSENVELT. Hypocalcemia. Severe hypocalcemia can occur, and fatal cases have been reported. Monitor calcium levels and calcium and vitamin D intake. Osteonecrosis of the Jaw (ONJ): ONJ can occur in patients on OSENVELT. Conduct oral exams and appropriate preventive dentistry before and during treatment; maintain oral hygiene and avoid invasive dental procedures; consider discontinuation of OSENVELT if ONJ develops. Atypical Subtrochanteric and Diaphyseal Femoral Fractures: Monitor for thigh, hip, or groin pain; evaluate for fractures. Interruption of OSENVELT therapy should be considered, pending a benefit-risk assessment, on an individual basis. Hypercalcemia Following Treatment Discontinuation in Patients with Giant Cell Tumor of Bone and in Patients with Growing Skeletons. Clinically significant hypercalcemia, potentially requiring hospitalization, can occur within a year after stopping denosumab in patients with giant cell tumor of bone or growing skeletons; monitor serum calcium and manage calcium and vitamin D needs post-discontinuation. Multiple Vertebral Fractures (MVF) Following Treatment Discontinuation. Increased risk post-discontinuation of denosumab; evaluate for risk for vertebral fractures after discontinuing OSENVELT. Embryo-Fetal Toxicity. Denosumab may cause fetal harm; verify pregnancy status before starting OSENVELT and advise effective contraception during treatment and for 5 months after the last dose. Most common Adverse Reactions: Bone Metastasis from Solid Tumors (≥ 25%) were fatigue/asthenia, hypophosphatemia, and nausea. In patients (≥ 10%) with: Multiple Myeloma were diarrhea, nausea, anemia, back pain, thrombocytopenia, peripheral edema, hypocalcemia, upper respiratory tract infection, rash, and headache; Giant Cell Tumor of Bone were arthralgia, headache, nausea, back pain, fatigue, and pain in extremity. Hypercalcemia of Malignancy (> 20%) were nausea, dyspnea, decreased appetite, headache, peripheral edema, vomiting, anemia, constipation, and diarrhea. For more information, see Full Prescribing Information. About Celltrion, Inc. Celltrion is a leading biopharmaceutical company that specializes in researching, developing, manufacturing, marketing and sales of innovative therapeutics that improve people's lives worldwide. Celltrion is a pioneer in the biosimilar space, having launched the world's first monoclonal antibody biosimilar. Our global pharmaceutical portfolio addresses a range of therapeutic areas including immunology, oncology, hematology, ophthalmology and endocrinology. Beyond biosimilar products, we are committed to advancing our pipeline with novel drugs to push the boundaries of scientific innovation and deliver quality medicines. For more information, please visit our website and stay updated with our latest news and events on our social media - LinkedIn, Instagram, X, and Facebook. About Celltrion USA Celltrion USA is Celltrion's U.S. subsidiary established in 2018. Headquartered in New Jersey, Celltrion USA is committed to expanding access to innovative biologics to improve care for U.S. patients. Celltrion's FDA-approved biosimilar products in immunology, oncology, hematology, and endocrinology include: INFLECTRA® (infliximab-dyyb), TRUXIMA® (rituximab-abbs), HERZUMA® (trastuzumab-pkrb), VEGZELMA® (bevacizumab-adcd), YUFLYMA®(adalimumab-aaty), AVTOZMA® (tocilizumab-anho), STEQEYMA® (Ustekinumab-stba) STOBOCLO® (denosumab-bmwo), OSENVELT® (denosumab-bmwo), and OMLYCLO® (omalizumab-igec), as well as the novel biologic ZYMFENTRA® (infliximab-dyyb). Celltrion USA will continue to leverage Celltrion's unique heritage in biotechnology, supply chain excellence and best-in-class sales capabilities to improve access to high-quality biopharmaceuticals for U.S. patients. For more information, please visit and stay updated with our latest news and events on our social media - LinkedIn. FORWARD-LOOKING STATEMENT Certain information set forth in this press release contains statements related to our future business and financial performance and future events or developments involving Celltrion, Inc. and its subsidiaries that may constitute forward-looking statements, under pertinent securities laws. These statements may be also identified by words such as "prepares", "hopes to", "upcoming", "plans to", "aims to", "to be launched", "is preparing", "once gained", "could", "with the aim of", "may", "once identified", "will", "working towards", "is due", "become available", "has potential to", the negative of these words or such other variations thereon or comparable terminology. In addition, our representatives may make oral forward-looking statements. Such statements are based on the current expectations and certain assumptions of Celltrion, Inc. and its subsidiaries' management, of which many are beyond its control. Forward-looking statements are provided to allow potential investors the opportunity to understand management's beliefs and opinions in respect to the future so that they may use such beliefs and opinions as one factor in evaluating an investment. These statements are not guarantees of future performance and undue reliance should not be placed on them. Such forward-looking statements necessarily involve known and unknown risks and uncertainties associated with the company's business, including the risk factors disclosed in its Annual Report and/or Quarterly Reports, which may cause actual performance and financial results in future periods to differ materially from any projections of future performance or results expressed or implied by such statements. Celltrion, Inc. and its subsidiaries undertake no obligation to update forward-looking statements if circumstances or management's estimates or opinions should change except as required by applicable securities laws. Trademarks STOBOCLO® and OSENVELT® are registered trademarks of Celltrion, and XGEVA® are registered trademarks of Amgen Inc. References [1] STOBOCLO U.S. prescribing information (2025) [2] OSENVELT U.S. prescribing information (2025) US-CT-P41-25-00006 For further information please contact:Andria Arenaaarena@ 516-578-0057 View original content to download multimedia: SOURCE Celltrion Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
Governor reveals ‘Make Oklahoma Healthy Again' plan with RFK for bans on soda, red dye
Gov. Kevin Stitt, center, pens his name during a ceremonial signing of an executive order to "Make Oklahoma Healthy Again," as Robert F. Kennedy Jr., right, the nation's secretary of health, and other supporters look on Thursday, June 26, 2025. (Photo by Janelle Stecklein/Oklahoma Voice) OKLAHOMA CITY — In a move quickly panned by licensed health care providers, Gov. Kevin Stitt announced Thursday that he planned to 'Make Oklahoma Healthy Again' by urging state agencies to stop supporting public water fluoridation, removing red food dyes from school and prison meals, and by asking the federal government to approve a request that bans food stamp recipients from purchasing soda and candy. Stitt's pledge came minutes after Robert F. Kennedy Jr., the nation's secretary of Health and Human Services, criticized the state for having the 47th worst health outcomes during a raucous 'MOHA' kickoff rally that drew hundreds of people to the state Capitol. Oklahoma has become the latest conservative state to submit a waiver to the U.S. Department of Agriculture that seeks to ban the state's Supplemental Nutrition Assistance Program recipients from using their benefits to buy sodas, candies and other confectionery items, Stitt said. Tax dollars will no longer 'continue to fund foods that are making people sick,' he said. State officials will also work with the U.S. Department of Agriculture to find more ways to promote healthly eating and to make food stamp funding go further. 'Eating healthy foods today is going to reduce health care spending and dietary related illnesses later on in life,' Stitt said. The Republican governor also said he's instructed the Oklahoma State Department of Health to stop recommending fluoride in public water. 'Cities and water districts, they can still choose to do what they want, based on their constituents and the science, but it's no longer going to be a recommendation for the state health department,' Stitt said. And Stitt said he's instructed all state agencies that provide meals to Oklahomans to discontinue their use of artificial dyes. He also plans to convene an advisory counsel to recommend other changes that can improve health outcomes across the state. Stitt's plans immediately faced criticism from licensed medical providers who showed up en masse at the rally, holding signs reading 'Support Evidence-Based Health Care', 'Encourage Immunizations' and 'Protect Medicaid.' Dr. Steven Crawford, chair of the Oklahoma Alliance for Healthy Families, said it would be 'disastrous' for children's health to remove fluoride from water. 'We do know that appropriate public water fluoridation prevents cavities,' he said. 'And how do you help children get better nutrition when they don't have adequate dentition or teeth to be able to eat the food? So I am so sad that the governor is advocating removing appropriate fluoride from public water.' Crawford, who practices medicine in Oklahoma City, said fluoridation of public water and immunizations are two of the major health benefits over the past century and have been critical to improving the state's and nation's health outcomes. He said removing candy and sugary drinks from the list of approved food stamp items isn't inappropriate, but Stitt neglected to mention that many recipients already don't get enough resources to be able to buy healthy foods. The governor also didn't discuss increasing food stamp funding to ensure children are getting adequate nutrition, particularly during the summer months when they are not eating at school, he said. Kennedy, who participated in a staged, ceremonial executive order signing with Stitt, praised the governor's actions. 'I am so gratified by these actions that are being taken by Gov. Stitt to make Oklahoma healthy again,' Kennedy said. Spectators heckled Kennedy throughout his speech that focused on America's soaring rates of obesity, diabetes and autism, declines in the nation's fertility rates and a drop in American teenage boys' testosterone levels. Kennedy, who has been criticized as being a vaccine skeptic, did not mention immunizations during his address. At one point, a state trooper could be seen escorting two bystanders from the crowd after one began shouting something unintelligible at Kennedy. A spokesperson for the Oklahoma Highway Patrol did not immediately respond to a request for comment about the encounter. Kennedy said when people ask him if he's taking soda and sugary drinks away from the Americans, he tells them that they should have the right to drink a bottle of soda. 'We live in a country where we have individual freedom,' he said. The federal government just should not be paying for it, he said. 'We're paying for them at the front end by buying soda for the poorest Americans, and then we're paying for it (on) the back end with this diabetes, for Medicaid and Medicare,' Kennedy said. 'And it doesn't make any sense. We are poisoning the American people.' He said electing leaders like Stitt will change the way we do things in the U.S. to give American children a better chance of growing up healthy. SUBSCRIBE: GET THE MORNING HEADLINES DELIVERED TO YOUR INBOX SUPPORT: YOU MAKE OUR WORK POSSIBLE